The Journal of Experimental Medicine
PBL InterferonSource
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 28 March 2005 doi:10.1084/jem.20042384
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 201, Number 7, 1031-1036
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 610K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bunde, T.
Right arrow Articles by Kern, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bunde, T.
Right arrow Articles by Kern, F.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Cytomegalovirus Infections
*Heart Transplantation
*Lung Transplantation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

BRIEF DEFINITIVE REPORT

 Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells

Torsten Bunde1, Alexander Kirchner1, Bodo Hoffmeister1, Dirk Habedank3, Roland Hetzer3, Georgy Cherepnev1, Susanna Proesch2, Petra Reinke4, Hans-Dieter Volk1, Hans Lehmkuhl3, and Florian Kern1

1 Institut für Medizinische Immunologie, Charité, Universitätsmedizin Berlin, Campus Mitte, 10098 Berlin, Germany
2 Institut für Virologie, Charité, Universitätsmedizin Berlin, Campus Mitte, 10098 Berlin, Germany
3 Deutsches Herzzentrum, 13353 Berlin, Germany
4 Medizinische Klinik mit Schwerpunkt Nephrologie und internistische Intensivmedizin, Charité, Campus Virchow-Klinikum, 13353 Berlin, Germany

CORRESPONDENCE Florian Kern: florian.kern{at}charite.de

T cells are crucial for the control of cytomegalovirus (CMV) in infected individuals. Although CMV-specific T cells can be quantified by various methods, clear correlates of protection from CMV disease have not been defined. However, responses to the pp65 protein are believed to play an important role. Here, the proportions of interferon {gamma}–producing T cells following ex vivo activation with pools of overlapping peptides representing the pp65 and immediate early (IE)-1 proteins were determined at multiple time points and related to the development of CMV disease in 27 heart and lung transplant recipients. Frequencies of IE-1–specific CD8 T cells above 0.2 and 0.4% at day 0 and 2 wk, respectively, or 0.4% at any time during the first months discriminated patients who did not develop CMV disease from patients at risk, 50–60% of whom developed CMV disease. No similar distinction between risk groups was possible based on pp65-specific CD8 or CD4 T cell responses. Remarkably, CMV disease developed exclusively in patients with a dominant pp65-specific CD8 T cell response. In conclusion, high frequencies of IE-1 but not pp65-specific CD8 T cells correlate with protection from CMV disease. These results have important implications for monitoring T cell responses, adoptive cell therapy, and vaccine design.

T. Bunde and A. Kirchner share senior authorship for this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS